GLP-1 drugs like semaglutide show promise for alcohol use disorder and obesity, but systemic drivers of addiction and metabolic health remain unaddressed
Original framing: “[Articles] Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial” — The Lancet
The trial demonstrates that GLP-1 receptor agonists like semaglutide can reduce alcohol consumption and body weight in a controlled setting, aligning with preclinical evidence linking GLP-1 to reward pathways in the brain. However, the study’s narrow focus on a pharmaceutical intervention overlooks the broader scientific consensus that metabolic health and addiction are influenced by environmental factors, including diet, stress, and socioeconomic status. The lack of long-term follow-up or comparison with non-pharmaceutical interventions limits the generalizability of the findings.
The trial’s focus on semaglutide as a solution to alcohol use disorder and obesity reflects a biomedical paradigm that medicalizes social problems while obscuring the structural forces—corporate food systems, socioeconomic inequality, and cultural normalization of addictive substances—that drive these epidemics.
This narrow framing ignores the wisdom of traditional healing systems, which have long addressed addiction and metabolic health through holistic, community-centered approaches, as well as the historical patterns of commodifying human vulnerabilities for profit. Marginalized communities, disproportionately affected by these issues, are often excluded from both the research and the solutions, reinforcing cycles of inequity. A systemic response must integrate pharmaceutical innovations with policy reforms, traditional healing practices, and community-based prevention, recognizing that healing is not just a chemical or clinical issue but a cultural and societal one. The trickster’s wisdom reminds us that true progress requires disrupting the absurdity of profit-driven systems that create the problems they claim to solve, while embracing the paradox that sometimes the most effective solutions lie outside the dominant paradigm.